Healthcare Roundup – Gilead’s remdesivir OK’d in Australia for COVID-19, Beroni inks supply deal in Japan for COVID-19 test

Published on: July 11, 2020
Author: Amy Liu

Gilead’s remdesivir OK’d in Australia for COVID-19

Australia’s Therapeutic Good Administration has granted provisional approval to Gilead Sciences’ (NASDAQ:GILD) Veklury (remdesivir) for the treatment of hospitalized adolescent and adult patients with COVID-19.

Remdesivir was previously approved in the U.S., Europe, India and Japan.

The company out-licensed non-exclusive rights to the antiviral to certain generic drugmakers aimed at distribution in 127 low- and middle-income countries.

Beroni inks supply deal in Japan for COVID-19 test

Beroni Group (OTCQX:BNIGF) partners with Forsitech and Standard Capital to supply its SARS-CoV-2 total antibody detection kit for clinical testing in the Japanese market.

Distribution will start with an initial supply of 100K test kits.

The delivery will be channelized through Standard Capital’s digital security token offerings platform, ALLEX, to asymptomatic patients who wish to be tested for antibodies.

Financial terms are not disclosed.

Halo Labs receives OK for Bophelo acquisition

Halo Labs (OTCQX:AGEEF) has obtained regulatory approval from South Africa’s Central Lesotho Bank to proceed with its proposed acquisition of cannabis producer Bophelo Bioscience & Wellness, expected to close by month-end.

Currently, Bophelo leases a 5-hectare fully licensed greenhouse canopy and has conditional approval to expand to a total of 200 hectares of licensed outdoor canopy.

Post the acquisition, Halo will secure a fully licensed export business, with potential access to European, Israeli and Australian cannabis markets.

Bophelo export sales under license are expected to commence from 1Q21.

Hologic coronavirus test shows 100% sensitivity in study

Hologic (HOLX +0.1%) is up modestly on below-average volume on the heels of the publication of performance characteristics of its SARS-CoV-2 molecular test performed on its automated Panther system.

The test showed concordance of 100% in sensitivity and 98.7% in specificity with validated PCR results for SARS-CoV-2 RNA.

The test’s analytical sensitivity was 100% using three commercially available SARS-CoV-2 nucleic acid controls with no cross-reactivity or interference with six related human coronaviruses as well as 24 other viral, fungal and bacterial antigens, all at high titer.

The FDA signed off on emergency use of the assay for COVID-19 in May.

Aytu Bio expands U.S. distribution of COVID-19 blood test with Apollo deal

Aytu BioScience (NASDAQ:AYTU) has signed a distribution agreement with Apollo Med Innovations to distribute its COVID-19 IgG/IgM Rapid Test Cassette to Apollo’s network of over 1,000 practices across the U.S.

Apollo will introduce the test as part of a comprehensive support program for professional medical organizations, integrated wellness centers, employers and municipalities.

Financial terms are not disclosed.

AYTU +5% PM.

Biotechnology COVID-19 Genomics Healthcare Services Life Science Medical Device Pharmaceutical